shopping cart
nothing in cart
 
browse by subject
new releases
best sellers
sale books
browse by author
browse by publisher
home
about us
upcoming events
Jul 6th - Essential Skills for the New Supervisor: Making the successful transition to supervisor [SickKids CCMH Learning Institute]
Jul 6th - Certificate for New Supervisors: Develop and enhance your supervisory skills in the Health and Human Service sector - live webinar [SickKids CCMH Learning Institute]
Jul 7th - Leadership and Motivation for Supervisors: Engage and inspire employees to achieve success and motivate performance [SickKids CCMH Learning Institute]
Jul 8th - Holding Difficult Conversations for Supervisors: An essential skill for a supervisor [SickKids CCMH Learning Institute]
Jul 9th - Building and Sustaining your Credibility and Influence as a New Supervisor [SickKids CCMH Learning Institute]
schools agencies and other institutional orders (click here)
Free shipping across Canada for all orders over $50. Please read our Covid-19 statement here.
Join our mailing list! Click here to sign up.
Alzheimer's Disease: Targets for New Clinical Diagnostic and Therapeutic Strategies | Frontiers in Neuroscience series
Wegrzyn, Renee D. and Alan S. Rudolph (Eds)
CRC Press / Hardcover / 2012-04-01 / 1439827087
Dementia
price: $273.95 (may be subject to change)
298 pages
Not in Stock, usually ships in 3-6 business days

In recent years, a tremendous amount of effort has been focused on better understanding the fundamentals of Alzheimer's disease (AD) to facilitate early and accurate diagnosis and appropriately targeted therapeutic treatments.Alzheimer's Disease: Targets for New Clinical, Diagnostic, and Therapeutic Strategiesprovides a detailed synopsis of the current state of the art of diagnostics and therapeutics and identifies emerging technologies and molecules that show promise in the management and treatment of AD.


With contributions from experts drawn from academia, clinical practice, and the biotechnology and pharmaceutical industries, the book explores:

• The basis of AD and the role of Aβ oligomers in development of disease
• Existing and emergingin vitrobiomarker-based methodologies for the diagnosis of AD, focusing on genetic, biochemical, and conformational strategies
• In vivoimaging diagnostic approaches
• Evolving diagnostic criteria, health regulatory guidelines, biomarkers in clinical trials, and available and emerging therapies
• Recent progress in small-molecule disease-modifier drug discovery efforts for AD, specifically in the areas of Aβ, tau, and emerging neuroprotective/neurorepair approaches
• How a case study of AD raises issues regarding clinical and pathologic criteria, risk factors, and the amyloid hypothesis
• The molecular conformational factors that govern the pathogenicity of aggregating proteins, and how these factors could represent new targets for disease-modifying therapies
• The latest epidemiological, pathological, biochemical, and behavioral studies that may shed some light on the risk of developing AD and similar dementias after traumatic brain injury

Examining current hypotheses and suggesting possible new approaches to therapeutic clinical applications, this volume paves the way for a robust pipeline of therapeutics to combat not only AD, but a whole host of other neurodegenerative diseases.

About the Editors:

Renee D. Wegrzyn obtained her PhD in applied biology from the Georgia Institute of Technology where she studied the propagation of prion proteins in model systems. Dr. Wegrzyn was awarded an Alexander von Humboldt Research Fellowship for her postdoctoral studies to investigatede novoprotein folding at the ribosome. She applied her expertise in protein folding to the challenge of developingin vitrodiagnostics for neurodegenerative diseases-including Alzheimer's and prion diseases-as a group leader at Adlyfe, Inc. She is currently a scientific and technical consultant for the Department of Defense.

Alan S. Rudolph is currently a member of the senior executive service and director of Biological and Chemical Technologies for the Defense Threat Reduction Agency. He was previously chief executive officer at Adlyfe Inc., an amyloid diagnostic and biomarker company, chief of Biological Sciences at the Defense Advanced Research Projects Agency, and director of Research at the Naval Research Laboratory. He has over 90 publications in diverse areas in biophysics of cryobiology and anhydrobiosis, lipid and protein self-assembly, liposome science and technology, and tissue and cellular engineering. He has a PhD in zoology from the University of California at Davis and an MBA from the George Washington University.

Caversham Booksellers
98 Harbord St, Toronto, ON M5S 1G6 Canada
(click for map and directions)
All prices in $cdn
Copyright 2020

Phone toll-free (800) 361-6120
Tel (416) 944-0962 | Fax (416) 944-0963
E-mail [email protected]
Hours: 9-6 Mon-Sat / Closed Sunday (EST)

search
Click here to read previous issues.
other lists
Dementia
Taylor and Francis